Published in Br J Pharmacol on August 01, 2011
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
Genome-wide approaches for identifying genetic risk factors for osteoporosis. Genome Med (2013) 1.09
Endocannabinoids are conserved inhibitors of the Hedgehog pathway. Proc Natl Acad Sci U S A (2015) 0.85
Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations. Int J Mol Sci (2013) 0.84
Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling. J Clin Invest (2015) 0.84
Themed issue on cannabinoids in biology and medicine. Br J Pharmacol (2011) 0.76
Inhibition of FAAH confers increased stem cell migration via PPARα. J Lipid Res (2015) 0.75
Levels of bioactive lipids in cooking oils: olive oil is the richest source of oleoyl serine. J Basic Clin Physiol Pharmacol (2016) 0.75
Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 5.95
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
FSH directly regulates bone mass. Cell (2006) 4.64
TSH is a negative regulator of skeletal remodeling. Cell (2003) 4.34
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng (2006) 3.46
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet (2008) 2.88
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int (1986) 2.71
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
A neuroscientist's guide to lipidomics. Nat Rev Neurosci (2007) 1.87
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A (2001) 1.41
Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem (2005) 1.39
Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta (2010) 1.38
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet (1998) 1.32
Modulation of osteoclastogenesis by fatty acids. Endocrinology (2008) 1.25
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol (2010) 1.19
The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone (2008) 1.16
The in vivo anabolic actions of prostaglandins in bone. Bone (1997) 1.15
Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet (2005) 1.13
In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res (1994) 1.08
Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab (2009) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet (2001) 1.03
Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol (2008) 1.02
The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone (2011) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition. J Anesth (2010) 1.00
Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int (2007) 1.00
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
NPY regulation of bone remodelling. Neuropeptides (2009) 0.99
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol (2010) 0.98
Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med (2007) 0.96
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
A study of bone marrow and subcutaneous fatty acid composition in subjects of varying bone mineral density. Bone (2009) 0.93
CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB J (2002) 0.92
N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91
Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet (2005) 0.91
Targeted lipidomics approach for endogenous N-acyl amino acids in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.90
Targeted lipidomics as a tool to investigate endocannabinoid function. Int Rev Neurobiol (2009) 0.89
Multiple osteoporosis susceptibility genes on chromosome 1p36 in Chinese. Bone (2009) 0.85
Retracted Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood (2010) 0.85
Adaptive condylar growth and mandibular remodelling changes with bionator therapy--an implant study. Eur J Orthod (2004) 0.84
Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res (2010) 0.82
The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. Hum Genet (2009) 0.80
Expression of selected osteogenic markers in the fibroblast-like cells of rat marrow stroma. Calcif Tissue Int (1995) 0.78
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum (2004) 1.67
Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res (2004) 1.59
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2003) 1.50
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2004) 1.43
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J (2006) 1.28
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab (2005) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther (2002) 1.20
The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis (2005) 1.19
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 1.19
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem (2008) 1.18
Endocannabinoids and traumatic brain injury. Br J Pharmacol (2011) 1.14
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia (2009) 1.11
Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol (2003) 1.11
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology (2007) 1.09
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol (2013) 1.08
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke (2003) 1.07
Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) (2003) 1.06
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res (2006) 1.06
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol (2011) 1.05
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 1.05
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol (2012) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions. J Clin Invest (2013) 1.02
Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol (2009) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) (2004) 1.01
Targeted lipidomics: fatty acid amides and pain modulation. Prostaglandins Other Lipid Mediat (2004) 1.00
Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord (2005) 1.00
Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol (2011) 1.00
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem (2007) 0.99
Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J (2008) 0.99
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol (2009) 0.99
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav (2005) 0.97
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 0.97
Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis (2005) 0.96
Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab (2008) 0.96
N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab (2011) 0.95
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci (2007) 0.95
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci (2002) 0.94
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res (2003) 0.94
N-Acyl amino acids and their impact on biological processes. Biofactors (2014) 0.93
Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol (2007) 0.93
Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res (2011) 0.93
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol (2006) 0.92
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport (2002) 0.92
Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev (2007) 0.92
Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J (2007) 0.91
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology (2005) 0.91
Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol (2008) 0.91
Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett (2007) 0.91
GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS One (2013) 0.90
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther (2007) 0.90
Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int (2004) 0.90
A GPR18-based signalling system regulates IOP in murine eye. Br J Pharmacol (2013) 0.90
Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol (2012) 0.89
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem (2004) 0.87
Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem (2010) 0.87
Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol (2008) 0.87
Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci (2003) 0.87
Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol (2008) 0.86
Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des (2008) 0.84
N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab (2013) 0.83
Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) (2007) 0.83
Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology (2005) 0.83
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis (2007) 0.82
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett (2006) 0.82
Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis (2009) 0.82
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull (2005) 0.81
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci (2008) 0.81
Long-term consequences of perinatal fatty acid amino hydrolase inhibition. Br J Pharmacol (2014) 0.81
A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. J Pharmacol Exp Ther (2007) 0.81
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma (2003) 0.81
Mo(CO)6-mediated intramolecular Pauson-Khand reaction of substituted diethyl 3-allyloxy-1-propynylphosphonates. J Org Chem (2009) 0.80
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem (2005) 0.80
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol (2004) 0.80
Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig (2014) 0.79
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol (2003) 0.79
Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci (2011) 0.78
A new UV-B absorbing mycosporine with photo protective activity from the lichenized ascomycete Collema cristatum. Eur J Biochem (2004) 0.78
Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. World J Biol Psychiatry (2013) 0.77
Cannabis--a valuable drug that deserves better treatment. Mayo Clin Proc (2012) 0.77
PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I. Inflammopharmacology (2004) 0.77
Intraperirhinal cortex administration of the synthetic cannabinoid, HU210, disrupts object recognition memory in rats. Neuroreport (2015) 0.76
Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury. J Neuroimmune Pharmacol (2015) 0.76
Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol (2016) 0.76